Onconova’s ASH poster to focus on narazaciclib in MCL

Onconova Therapeutics announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023. “The poster that we and researchers from the Josep Carreras Leukaemia Research Institute in Barcelona, Spain are presenting at ASH 2023 shows that the study of narazaciclib, either as a single agent or in combination with ibrutinib, effectively controls tumor growth in preclinical models of mantle cell lymphoma, including those that are resistant to Bruton’s tyrosine kinase inhibitors, a mainstay of care for this aggressive and difficult to treat cancer. The experiments included a broad comparison of narazaciclib with three other approved cyclin-D-kinase inhibitors, used in combination with several BTKis,” said Steven Fruchtman, M.D., President and CEO of Onconova.